Nicholas Von Guionneau
Analyst at Catalio Capital Management
United Kingdom
Overview
Work Experience
Senior Analyst
2021 - Current
Analyst
2021 - 2021
Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.
Board Observer
2024
Board Observer
2023
Board Observer
2022
Non Executive Director
2022
Board Observer
2022 - 2022
Board Observer
2021
SetPoint Medical develops novel therapeutics for the treatment of chronic autoimmune conditions.
Raised $344,000,000.00 from Citta Capital, SVE Capital, Shangbay Capital, Gilmartin Capital LLC, New Enterprise Associates, Boston Scientific, Action Potential Venture Capital, Richard King Mellon Foundation and Euclidean Capital.
Board Observer
2022
LifeSprout offers revolutionary products for soft tissue replacement and regeneration
Raised $35,800,000.00 from Triskelion Capital, Redmile Group, Camden Partners, Abell Foundation, Nexus Capital Management and Emerald Development Managers.
Board Observer
2022 - 2024
Blackrock Neurotech is the platform for brain-computer interface (BCI) technology and manufacturing.
Raised $10,000,000.00 from What If Ventures, Arda Kara, Presight Capital, WPSS.bio and Kliwla Family Office AG.
Postdoctoral Research Fellow
2018 - 2021
Department of Plastic and Reconstructive Surgery Peripheral Nerve Laboratory Translational peripheral nerve research with Dr Sami Tuffaha. Development of: - nanoparticle-based drug delivery system - neurotherapeutics to improve nerve regeneration - intraoperative nerve imaging device - implantable nerve stimulators - nerve wraps - novel pre-clinical functional outcome assessments
One of the leading health care systems in the United States.
Medical Doctor
2016 - 2017
General Surgery, Renal Transplant Surgery, End-Stage Renal Medicine, Geriatrics